157 related articles for article (PubMed ID: 22146565)
1. Evaluation of inhaled cidofovir as postexposure prophylactic in an aerosol rabbitpox model.
Verreault D; Sivasubramani SK; Talton JD; Doyle LA; Reddy JD; Killeen SZ; Didier PJ; Marx PA; Roy CJ
Antiviral Res; 2012 Jan; 93(1):204-8. PubMed ID: 22146565
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease.
Trost LC; Rose ML; Khouri J; Keilholz L; Long J; Godin SJ; Foster SA
Antiviral Res; 2015 May; 117():115-21. PubMed ID: 25746331
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.
Rice AD; Adams MM; Wallace G; Burrage AM; Lindsey SF; Smith AJ; Swetnam D; Manning BR; Gray SA; Lampert B; Foster S; Lanier R; Robertson A; Painter G; Moyer RW
Viruses; 2011 Jan; 3(1):47-62. PubMed ID: 21373379
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbits.
Grossi IM; Foster SA; Gainey MR; Krile RT; Dunn JA; Brundage T; Khouri JM
Antiviral Res; 2017 Jul; 143():278-286. PubMed ID: 28392420
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.
Rice AD; Adams MM; Lampert B; Foster S; Robertson A; Painter G; Moyer RW
Viruses; 2011 Feb; 3(2):63-82. PubMed ID: 21369346
[TBL] [Abstract][Full Text] [Related]
6. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice.
Smee DF; Wong MH; Bailey KW; Beadle JR; Hostetler KY; Sidwell RW
Int J Antimicrob Agents; 2004 May; 23(5):430-7. PubMed ID: 15120719
[TBL] [Abstract][Full Text] [Related]
7. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype.
Kornbluth RS; Smee DF; Sidwell RW; Snarsky V; Evans DH; Hostetler KY
Antimicrob Agents Chemother; 2006 Dec; 50(12):4038-43. PubMed ID: 16982794
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model.
Nalca A; Hatkin JM; Garza NL; Nichols DK; Norris SW; Hruby DE; Jordan R
Antiviral Res; 2008 Aug; 79(2):121-7. PubMed ID: 18479761
[TBL] [Abstract][Full Text] [Related]
9. Antiviral prophylaxis of smallpox.
Bray M; Roy CJ
J Antimicrob Chemother; 2004 Jul; 54(1):1-5. PubMed ID: 15163655
[TBL] [Abstract][Full Text] [Related]
10. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir.
Bray M; Martinez M; Kefauver D; West M; Roy C
Antiviral Res; 2002 Jun; 54(3):129-42. PubMed ID: 12062386
[TBL] [Abstract][Full Text] [Related]
11. Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox.
Adams MM; Rice AD; Moyer RW
J Virol; 2007 Oct; 81(20):11084-95. PubMed ID: 17686856
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model.
Garza NL; Hatkin JM; Livingston V; Nichols DK; Chaplin PJ; Volkmann A; Fisher D; Nalca A
Vaccine; 2009 Sep; 27(40):5496-504. PubMed ID: 19632316
[TBL] [Abstract][Full Text] [Related]
13. Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus.
Zaitseva M; McCullough KT; Cruz S; Thomas A; Diaz CG; Keilholz L; Grossi IM; Trost LC; Golding H
J Virol; 2015 Mar; 89(6):3295-307. PubMed ID: 25589648
[TBL] [Abstract][Full Text] [Related]
14. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir.
Smee DF; Bailey KW; Sidwell RW
Antivir Chem Chemother; 2001 Jan; 12(1):71-6. PubMed ID: 11437324
[TBL] [Abstract][Full Text] [Related]
15. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice.
Smee DF; Bailey KW; Wong MH; Wandersee MK; Sidwell RW
J Infect Dis; 2004 Sep; 190(6):1132-9. PubMed ID: 15319864
[TBL] [Abstract][Full Text] [Related]
16. A Nucleic Acid-Based Orthopoxvirus Vaccine Targeting the Vaccinia Virus L1, A27, B5, and A33 Proteins Protects Rabbits against Lethal Rabbitpox Virus Aerosol Challenge.
Mucker EM; Golden JW; Hammerbeck CD; Kishimori JM; Royals M; Joselyn MD; Ballantyne J; Nalca A; Hooper JW
J Virol; 2022 Feb; 96(3):e0150421. PubMed ID: 34851148
[TBL] [Abstract][Full Text] [Related]
17. Smallpox vaccination and adverse reactions. Guidance for clinicians.
Cono J; Casey CG; Bell DM;
MMWR Recomm Rep; 2003 Feb; 52(RR-4):1-28. PubMed ID: 12617510
[TBL] [Abstract][Full Text] [Related]
18. Postexposure prevention of progressive vaccinia in SCID mice treated with vaccinia immune globulin.
Fisher RW; Reed JL; Snoy PJ; Mikolajczyk MG; Bray M; Scott DE; Kennedy MC
Clin Vaccine Immunol; 2011 Jan; 18(1):67-74. PubMed ID: 21106779
[TBL] [Abstract][Full Text] [Related]
19. Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox.
Wei H; Huang D; Fortman J; Wang R; Shao L; Chen ZW
J Virol; 2009 Jan; 83(2):1115-25. PubMed ID: 19004937
[TBL] [Abstract][Full Text] [Related]
20. Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge.
Roy CJ; Baker R; Washburn K; Bray M
Antimicrob Agents Chemother; 2003 Sep; 47(9):2933-7. PubMed ID: 12936997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
